As part of Trump's drug pricing plan, the administration wants to study whether drug copay coupons should be allowed in federal health care programs.
Why it matters: Federal kickback law prohibits pharmaceutical companies from offering drug coupons to Medicare and Medicaid patients because the coupons induce patients to choose certain medications even though cheaper alternatives might be available.